Analyst Consensus Forecast

Consensus forecasts1 2016-2018 full year results

CHF million 2016 2017 2018
Revenue 915.7 1001.0 1083.0
Growth in CHF (in %) 14.7% 9.3% 8.2%
Gross profit 716.3 787.7 855.6
Gross margin (in %) 78.2% 78.7% 79.0%
EBITDA 262.3 295.0 328.0
EBITDA margin (in %) 28.6% 29.5% 30.3%
EBIT 225.8 256.2 284.6
EBIT margin (in %) 24.7% 25.6% 26.3%
EPS (reported) 13.3 13.8 15.5

The following analysts / banks have contributed to this consensus:

  • Goldman Sachs, Veronika Dubajova
  • Morgan Stanley, Michael Jungling
  • ZKB Zürcher Kantonalbank, Sibylle Bischofberger
  • Bank am Bellevue, Daniel Jelovcan
  • Bank Vontobel, Carla Bänziger
  • J.P. Morgan Cazenove,  David Adlington
  • Credit Suisse, Christoph Gretler
  • BoA Merrill Lynch, Ines Duarte da Silva
  • AB Bernstein, Lisa Clive
  • MainFirst Bank, Markus Wieprecht
  • Commerzbank, Oliver Metzger
  • Jefferies, Chris Cooper
  • Exane BNP Paribas, Julien Dormois
  • UBS, Ian Douglas-Pennant
  • HSBC, Richard Latz

Note: For the year 2017, the company will benefit from two acquisition effects: 1) Full consolidation of Medentiak GmbH, Germany (51% ownership) and 2) acquisiton of equinox, India. These effects and currency fluctuations are included in the revenue line.  

1 This I/B/E/S consensus data represent all available analyst reports which have been issued 2 or 200 days ago.  This consensus has been issued for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Straumann did not participate in the compilation of the estimates and it does not endorse them. The company gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.

Latest update: 21. December 2016